Although TopIIα expression and its implication for TopII inhibitors have been extensively investigated in several cancers, especially in breast cancer, few reports have described TopIIα expression and its cross resistance to other cytotoxic drugs in NSCLC [10,11,14-16]. The gene discussed is TOP2A; the disease is non-small cell lung carcinoma.